This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzym…

VEXASVEXAS Syndrome

~Estimated

~$10 – $7,500

Swedish Orphan BiovitrumNCT06782373

Phase 1

A Phase 1 Study of Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

VEXAS (vacuoles, E1 ubiqutin-activating enzyme, X-linked, autoinflammatory, somatic syndrome) is a recently described disorder with severe hematologic and rheu…

E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic SyndromeVEXASVexas Syndrome

~Estimated

~$10 – $6,250

Washington University School of MedicineNCT06538181